慢性心力衰竭的医疗管理和基于设备的治疗方法
Andrew H Nguyen1, Madelyn Hurwitz2, Jacob Abraham3
1Inova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia.
概括
针对心力衰竭 (HF) 的指导指导医学疗法已经取得了进展,但局限性仍然存在. 基于设备的干预措施为治疗慢性HF和改善患者治疗结果提供了有希望的解决方案.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
背景情况:
- 心力衰竭是全球发病率和死亡率的主要原因之一.
- 目前的指南导向医学疗法 (GDMT) 提供了减少喷射分数 (HFrEF) 和保持喷射分数 (HFpEF) 的HF的进展.
研究的目的:
- 审查慢性HF的GDMT目前的景观.
- 讨论GDMT实施的局限性和障碍.
- 总结用于高频管理的基于设备的治疗方法.
主要方法:
- 对慢性心力衰竭的指导指导医学治疗的文献综述.
- 医学治疗实施和坚持的局限性分析.
- 对所有HF表型的既定和新兴设备式干预措施的审查.
主要成果:
- 尽管医学进步,但GDMT实施存在重大障碍,包括延迟,耐受性和成本.
- 相当数量的患者仍然表现出症状,结果不佳.
- 基于设备的干预措施显示出 HF 现型中的承诺和确定的有效性.
结论:
- 在HF管理中未满足的临床需求仍然存在,尽管最佳的医疗治疗.
- 基于设备的疗法代表了改善慢性心力衰竭结果的日益增长和重要领域.
- 综合医疗和设备治疗的综合方法对于有效的高频管理至关重要.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Heart Failure Drugs: Inotropic Agents
548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353


